Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate

European Journal of Clinical Investigation

Volumn 32, Issue 8, 2002, Pages 575-580

  Rudolph, G ^a   Kloeters Plachky, P ^a   Sauer, P ^a   Stiehl, Adolf ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Absorption; Cholestasis; Ursodeoxycholic acid

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; GLYCINE; LITHOCHOLIC ACID; TAURINE; URSODEOXYCHOLIC ACID;

ACID SECRETION; ADULT; AGED; ARTICLE; BILE DUCT OBSTRUCTION; BILE SECRETION; BILIARY TRACT DRAINAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUGATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTEROHEPATIC CIRCULATION; ENTEROPATHY; FEMALE; HUMAN; INTESTINE ABSORPTION; LIVER DISEASE; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; TIME;

AGED; ANALYSIS OF VARIANCE; BILE ACIDS AND SALTS; BILE DUCTS; CHOLESTASIS, EXTRAHEPATIC; FEMALE; HUMANS; INTESTINAL ABSORPTION; LITHOCHOLIC ACID; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TAURINE; URSODEOXYCHOLIC ACID;

EID: 0036997994     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01030.x     Document Type: Article

References (51)

1. Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-74.
2. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-54.
3. Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheeler DE et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-66.
4. Lindor KDL, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-90.
5. Heathcote EJL, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN et al. The Canadian multi-center double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
6. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
7. Beuers U, Spengler U, Kruis W, Aydemir Ü, Wiebecke B, Heldwein Wet al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology 1992;16:707-14.
8. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
9. Lindor KD and the Mayo PSC/UDCA study group. Ursodiol for the treatment of primary sclerosing cholangitis. N Engl J Med 1997;336:691-5.
10. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S et al. Efficacy of ursodeoxycholic acid and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997;26:560-6.
11. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
12. Mitchell SA, Bansi DS, Hunt N, von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis. Results of a randomized double-blind placebo-controlled study. Gastroenterology 2001;121:900-7.
13. Palma J, Reyes H, Ribalta J, Iglesias J, Gonzalez MC, Hernandez I et al. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology 1992;15:1043-7.
14. Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid therapy on nutrition and liver function in patients with cystic fibrosis and long-standing cholestasis. Gut 1990;31:918-21.
15. Colombo C, Setchell KDR, Podda M, Crosignani A, Roda A, Curcio L et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990;117:482-9.
16. Kitani K, Kitani S. Tauroursodeoxycholate prevents taurocholate-induced cholestasis. Life Sci 1982;30:515-23.
17. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990;12:486-91.
18. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak M, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts: in vivo studies in rat. Gastroenterology 1991;100:203-11.
19. Tsukahara K, Kanai S, Ohta M, Kitani K. Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats. Liver 1993;13:262-9.
20. Heuman DM, Dajaj R. Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. Gastroenterology 1994;106:1333-41.
21. Benz C, Angermüller S, Töx U, Klöters-Plachky P, Riedel HP, Sauer Pet al. Effect of tauroursodeoxycholic acid on bile acid induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 1998;28:99-106.
22. Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer J. Ursodeoxycholic acid prevents cytochrome C release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Diff 1999;6:842-54.
23. Que FG, Phan VA, Phan VH, LaRusso NF, Gores GJ. GUDC inhibits cytochrome C release from human cholangiocyte mitochondria. J Surg Res 1999;83:100-5.
24. Benz C, Angermüller S, Otto G, Stremmel W, Stiehl A. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest 2000;30:203-9.
25. Rodrigues CMP, Kren BT, Steer CJ, Setchell KD. Tauroursodeoxycholate increases rat liver ursodeoxycholate levels and limits lithocholate formation better than ursodeoxycholate. Gastroenterology 1995;109:564-72.
26. Crosignani A, Battezzati PM, Setchell KDR, Invernizzi P, Covini G, Zuin M et al. Taurursodeoxycholic acid for the treatment of primary biliary cirrhosis. A dose - response study. Dig Dis Sci 1996;41:809-15.
27. Invernizzi P, Setchell KDR, Crosignani A, Battezzati PM, Larghi A, O'Conell Net al. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 1999;29:320-7.
28. Born P, Rosch T, Willkomm G, Sandschin W, Fitz N, Weigert N et al. Initial experience with a new Yamakawa-type prosthesis for long-term percutaneous transhepatic drainage. Endoscopy 1999;31:748-50.
29. Stravitz RT, Sanyal AJ, Pandak WM, Vlahcevic ZR, Beets JW, Dawson PA. Induction of sodium-dependent bile acid transporter messenger RNA, protein, and activity in rat ileum by cholic acid. Gastroenterology 1997;113:1599-608.
30. Walker S, Rudolph G, Raedsch R, Stiehl A. Intestinal absorption of ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 1992;102:810-15.
31. Stiehl A, Raedsch R, Rudolph G, Czygan P, Walker S. Analysis of bile acid glucuronides in urine: group separation on a lipophilic anion exchanger. Clin Chim Acta 1982;123:275-85.
32. Alme B, Bremmelgaard A, Sjövall J, Thomassen P. Analysis of metabolic profiles of bile acid in urine using lipophilic anion exchanger and computerized gas liquid chromatography mass spectrometry. J Lipid Res 1977;18:339-61.
33. Sauer P, Benz C, Rudolph G, Kloeters-Plachky P, Stremmel W, Stiehl A. Influence of cholestasis on absorption of ursodeoxycholic acid. Dig Dis Sci 1999;44:817-22.
34. Stiehl A, Raedsch R, Rudolph G. Ileal excretion of bile acids: comparison with biliary bile acid composition and effect of ursodeoxycholic acid treatment. Gastroenterology 1988;94:1201-6.
35. Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic acid and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990;98:424-8.
36. Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995;23:283-9.
37. Fedorowski T, Salen G, Colallilo A, Tint GS, Mosbach EH, Hall JC. Metabolism of ursodeoxycholic acid in man. Gastroenterology 1977;73:1131-7.
38. Stiehl A, Raedsch R, Rudolph G, Walker S. Effect of ursodeoxycholic acid on biliary bile acid and bile lipid composition in gallstone patients. Hepatology 1984;4:107-11.
39. Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J et al. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989;10:414-19.
40. Nakagawa M, Colombo C, Setchell KDR. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology 1990;12:322-34.
41. Crosignani A, Battezzati PM, Bertolini M, Zuin M, Watson D, Setchell KDR. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991;14:1000-7.
42. Setchell KDR, Rodrigues CMP, Podda M, Crosignani A. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut 1996;38:439-46.
43. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990;98:1044-50.
44. Fromm H, Carlson GL, Hofmann AF, Farivar S, Amin P. Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acid. Am J Physiol 1980;239:G161-6.
45. Fedorowski T, Salen G, Tint GS, Mosbach E. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology 1979;77:1068-73.
46. Hofmann AF. Pharmacology of chenodeoxycholic acid and ursodeoxycholic acid in man. In: Paumgartner G, Stiehl A, Gerok W, editors. Bile acids and cholesterol in health and disease. Dordrecht: Kluwer Academic;1983.pp. 301-36.
47. Kanai S, Kitani K. Glycoursodeoxycholate is as effective as tauroursodeoxycholate in preventing the taurocholate-induced cholestasis in the rat. Res Commun Chem Pathol Pharmacol 1983;42:423-30.
48. Beuers U, Throckmorton DC, Anderson MS, Isales CM, Thasler W, Kullak-Ublick GA et al. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology 1996;110:1553-63.
49. Kurz AK, Graf D, Schmitt M, Vom Dahl S, Haussinger D. Taurursodeoxycholate-induced choleresis involves p38 (MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 2001;121:407-19.
50. Marteau P, Chazouilleres O, Myara A, Jian R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990;12:1206-8.
51. Hofmann AF. Bile acid hepatotoxicity and the rationale of UDCA therapy in chronic cholestatic liver disease: some hypotheses. In: Paumgartner G, Stiehl A, Barbara L, Roda E, editors. Strategies for the treatment of hepatobiliary diseases. Dordrecht: Kluwer Academic;1990. pp. 13-34.